Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDK12 dec exp |
| Therapy | Talazoparib |
| Indication/Tumor Type | colon cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDK12 dec exp | colon cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of a colon cancer cell line with decreased CDK12 expression in culture (PMID: 39321214). | 39321214 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39321214) | Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. | Full reference... |